Clinical characteristics and overall survival prognostic nomogram for metaplastic breast cancer

被引:7
作者
Zheng, Caihong [1 ,2 ,3 ]
Fu, Chengbin [2 ,3 ,4 ]
Wen, Yahui [1 ,2 ,3 ]
Liu, Jiameng [5 ]
Lin, Shunguo [2 ,3 ,4 ]
Han, Hui [2 ,3 ,4 ]
Han, Zhonghua [2 ,3 ,4 ]
Xu, Chunsen [2 ,3 ,4 ]
机构
[1] Fujian Med Univ, Grad Sch, Fuzhou, Fujian, Peoples R China
[2] Fujian Med Univ Union Hosp, Dept Breast Surg, Fuzhou, Fujian, Peoples R China
[3] Fujian Med Univ Union Hosp, Dept Gen Surg, Fuzhou, Fujian, Peoples R China
[4] Fujian Med Univ, Breast Canc Inst, Fuzhou, Fujian, Peoples R China
[5] Xiamen Univ, Dept Breast Surg, Women & Childrens Hosp, Sch Med, Xiamen, Fujian, Peoples R China
关键词
SEER; metaplastic breast cancer; nomogram; overall survival (OS); prognosis; CONSERVING SURGERY; VALIDATION; OUTCOMES; TUMORS; CURVE; RAD51;
D O I
10.3389/fonc.2023.1030124
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundMetaplastic breast cancer (MBC) is a rare breast tumor and the prognostic factors for survival in patients still remain controversial. This study aims to develop and validate a nomogram to predict the overall survival (OS) of patients with MBC. MethodsWe searched the Surveillance, Epidemiology, and End Results (SEER) database for data about patients including metaplastic breast cancer and infiltrating ductal carcinoma (IDC) from 2010 to 2018. The survival outcomes of patients between MBC and IDC were analyzed and compared with the Kaplan-Meier (KM) method. MBC patients were randomly allocated to the training set and validation I set by a ratio of eight to two. Meanwhile, the performance of this model was validated again by the validation II set, which consisted of MBC patients from the Union Hospital of Fujian Medical University between 2010 and 2018. The independent prognostic factors were selected by univariate and multivariate Cox regression analyses. The nomogram was constructed to predict individual survival outcomes for MBC patients. The discriminative power, calibration, and clinical effectiveness of the nomogram were evaluated by the concordance index (C-index), the receiver operating characteristic (ROC) curve, and the decision curve analysis (DCA). ResultsMBC had a significantly higher T stage (T2 and above accounting for 75.1% vs 39.9%), fewer infiltrated lymph nodes (N0 accounted for 76.2% vs 67.7%), a lower proportion of ER (22.2% vs 81.2%), PR (13.6% vs 71.4%), and HER-2(6.7% vs 17.7%) positive, radiotherapy(51.6% vs 58.0%) but more chemotherapy(67.5% vs 44.7%), and a higher rate of mastectomy(53.2% vs 36.8%), which was discovered when comparing the clinical baseline data between MBC and IDC. Age at diagnosis, T, N, and M stage, as well as surgery and radiation treatment, were all significant independent prognostic factors for overall survival (OS). In the validation I cohort, the nomogram's C-index (0.769 95% CI 0.710 -0.828) was indicated to be considerably higher than the standard AJCC model's (0.700 95% CI 0.644 -0.756). Nomogram's great predictive capability capacity further was supported by the comparatively high C-index of the validation II sets (0.728 95%CI 0.588-0.869). ConclusionsMetaplastic breast cancer is more aggressive, with a worse clinical prognosis than IDC. This nomogram is recommended for patients with MBC, both American and Chinese, which can help clinicians make more accurate individualized survival analyses.
引用
收藏
页数:14
相关论文
共 37 条
[1]   A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609) [J].
Adams, Sylvia ;
Othus, Megan ;
Patel, Sandip Pravin ;
Miller, Kathy D. ;
Chugh, Rashmi ;
Schuetze, Scott M. ;
Chamberlin, Mary D. ;
Haley, Barbara J. ;
Storniolo, Anna Maria, V ;
Reddy, Mridula P. ;
Anderson, Scott A. ;
Zimmerman, Collin T. ;
O'Dea, Anne P. ;
Mirshahidi, Hamid R. ;
Ahnert, Jordi Rodon ;
Brescia, Frank J. ;
Hahn, Olwen ;
Raymond, Jane M. ;
Biggs, David D. ;
Connolly, Roisin M. ;
Sharon, Elad ;
Korde, Larissa A. ;
Gray, Robert J. ;
Mayerson, Edward ;
Plets, Melissa ;
Blanke, Charles D. ;
Chae, Young Kwang ;
Kurzrock, Razelle .
CLINICAL CANCER RESEARCH, 2022, 28 (02) :271-278
[2]   The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging [J].
Amin, Mahul B. ;
Greene, Frederick L. ;
Edge, Stephen B. ;
Compton, Carolyn C. ;
Gershenwald, Jeffrey E. ;
Brookland, Robert K. ;
Meyer, Laura ;
Gress, Donna M. ;
Byrd, David R. ;
Winchester, David P. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) :93-99
[3]   Biology of breast cancer in young women [J].
Azim, Hatem A., Jr. ;
Partridge, Ann H. .
BREAST CANCER RESEARCH, 2014, 16 (04)
[4]   Nomograms in oncology: more than meets the eye [J].
Balachandran, Vinod P. ;
Gonen, Mithat ;
Smith, J. Joshua ;
DeMatteo, Ronald P. .
LANCET ONCOLOGY, 2015, 16 (04) :E173-E180
[5]   Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer [J].
Basho, Reva K. ;
Yam, Clinton ;
Gilcrease, Michael ;
Murthy, Rashmi K. ;
Helgason, Thorunn ;
Karp, Daniel D. ;
Meric-Bernstam, Funda ;
Hess, Kenneth R. ;
Valero, Vicente ;
Albarracin, Constance ;
Litton, Jennifer K. ;
Chavez-MacGregor, Mariana ;
Hong, David ;
Kurzrock, Razelle ;
Hortobagyi, Gabriel N. ;
Janku, Filip ;
Moulder, Stacy L. .
ONCOLOGIST, 2018, 23 (11) :1300-1309
[6]   Metaplastic carcinoma of the breast: Imaging and pathological features [J].
Bian, Tiantian ;
Lin, Qing ;
Wu, Zengjie ;
Cui, Chunxiao ;
Qi, Chunhua ;
Li, Li ;
Su, Xiaohui .
ONCOLOGY LETTERS, 2016, 12 (05) :3975-3980
[7]   RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer [J].
Cruz, C. ;
Castroviejo-Bermejo, M. ;
Gutierrez-Enriquez, S. ;
Llop-Guevara, A. ;
Ibrahim, Y. H. ;
Gris-Oliver, A. ;
Bonache, S. ;
Morancho, B. ;
Bruna, A. ;
Rueda, O. M. ;
Lai, Z. ;
Polanska, U. M. ;
Jones, G. N. ;
Kristel, P. ;
de Bustos, L. ;
Guzman, M. ;
Rodriguez, O. ;
Grueso, J. ;
Montalban, G. ;
Caratu, G. ;
Mancuso, F. ;
Fasani, R. ;
Jimenez, J. ;
Howat, W. J. ;
Dougherty, B. ;
Vivancos, A. ;
Nuciforo, P. ;
Serres-Creixams, X. ;
Rubio, I. T. ;
Oaknin, A. ;
Cadogan, E. ;
Barrett, J. C. ;
Caldas, C. ;
Baselga, J. ;
Saura, C. ;
Cortes, J. ;
Arribas, J. ;
Jonkers, J. ;
Diez, O. ;
O'Connor, M. J. ;
Balmana, J. ;
Serra, V .
ANNALS OF ONCOLOGY, 2018, 29 (05) :1203-1210
[8]   Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors [J].
Faraoni, Isabella ;
Graziani, Grazia .
CANCERS, 2018, 10 (12)
[9]   Recurrence and mortality after breast-conserving surgery without radiation [J].
Guidolin, K. ;
Lock, M. ;
Vogt, K. ;
McClure, J. A. ;
Winick-Ng, J. ;
Vinden, C. ;
Brackstone, M. .
CURRENT ONCOLOGY, 2019, 26 (06) :380-388
[10]   Metaplastic Breast Cancer: Practice Patterns, Outcomes, and the Role of Radiotherapy [J].
Haque, Waqar ;
Verma, Vivek ;
Naik, Nilan ;
Butler, E. Brian ;
Teh, Bin S. .
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (04) :928-936